SCM
IGMS

Sterling Capital Management’s IGM Biosciences IGMS Stock Holding History

Sterling Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18
Closed -$21 – 3319
2025
Q1 		$21 Hold
18
– – ﹤0.01% 3199
2024
Q4 		$110 Hold
18
– – ﹤0.01% 3171
2024
Q3 		$298 Buy
+18
New +$197 ﹤0.01% 3037

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Sterling Capital Management's IGMS Position: Q2 2025 in Review

Sterling Capital Management sold out of IGM Biosciences (IGMS) in Q2 2025, closing a stake of 18 shares — an estimated $21 sold.

Sterling Capital Management first reported a position in IGMS in Q3 2024 and held it in 3 quarters. The position peaked at $298 in Q3 2024. 66 funds tracked by Wall St. Rank hold IGMS as of Q2 2025.

  • Sterling Capital Management reported no remaining IGM Biosciences position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 18 IGM Biosciences shares in Q2 2025, an estimated $21.
  • Sterling Capital Management first reported a position in IGM Biosciences in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's IGM Biosciences position peaked at $298 in Q3 2024.
  • 66 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.